Rezolute is a late-stage biopharmaceutical company focused on developing innovative therapies for rare diseases, particularly those associated with hyperinsulinism. Their lead product, RZ358 (ersodetug), targets congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI), both of which can lead to dangerous hypoglycemic events. The company is currently conducting a Phase 3 clinical trial, known as the sunRIZE study, to evaluate the safety and efficacy of RZ358 in patients with cHI. Preliminary results from earlier studies indicate that RZ358 has the potential to significantly reduce hypoglycemic episodes, with improvements observed in nearly all participants. The company is also exploring the use of RZ402, an oral plasma kallikrein inhibitor, for the treatment of diabetic macular edema (DME), a serious complication of diabetes that affects vision.

Rezolute's commitment to patient-centered care drives their research and development efforts, ensuring that the needs of patients and their families are prioritized in every aspect of their work. The company collaborates with global partners to address the challenges posed by hyperinsulinism and other rare diseases, aiming to restore balance and improve the quality of life for affected individuals. Their innovative approach combines rigorous clinical trials with a focus on transformative therapies, reflecting their dedication to making a meaningful impact in the biopharmaceutical landscape.

United States

Rezolute is a clinical stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic disorders. They are focused on advancing their pipeline of drug candidates to address unmet medical needs in diabetes, obesity, and other metabolic disorders.

Rezolute

Company Details